Characteristics | Derivation cohort (n = 124) | Validation cohort (n = 72) | P | ||
---|---|---|---|---|---|
nonrecovery (n = 52) | recovery (n = 72) | nonrecovery (n = 31) | recovery (n = 41) | ||
sex (male), n (%) | 43 (82.7) | 40 (55.6) | 25 (80.6) | 27 (65.9) | 0.005a |
age (yr) | 60 ± 10 | 56 ± 12 | 62 ± 9 | 56 ± 13 | 0.023b |
SBP (mmHg) | 146 ± 25 | 141 ± 21 | 147 ± 23 | 142 ± 19 | 0.523 |
DBP (mmHg) | 81 ± 12 | 82 ± 14 | 80 ± 12 | 82 ± 13 | 0.865 |
hgb(g/l) | 125 ± 21 | 126 ± 17 | 122 ± 18 | 125 ± 17 | 0.863 |
glucose (mmol/l) | 5.3 ± 1.4 | 4.9 ± 1.1 | 4.9 ± 1.2 | 5.0 ± 1.3 | 0.383 |
TC (mmol/l) | 8.3 ± 2.4 | 8.2 ± 2.9 | 8.0 ± 2.0 | 7.9 ± 2.9 | 0.860 |
TG (mmol/l) | 3.3 ± 3.0 | 3.1 ± 2.1 | 2.9 ± 1.7 | 3.2 ± 2.5 | 0.875 |
HDL (mmol/l) | 1.3 ± 0.4 | 1.4 ± 1.1 | 1,3 ± 0.4 | 1.3 ± 0.6 | 0.689 |
LDL (mmol/l) | 5.0 ± 2.2 | 4.8 ± 2.2 | 4.8 ± 1.7 | 4.5 ± 2.1 | 0.660 |
Scrmax (umol/l) | 121 ± 32 | 111 ± 27 | 122 ± 34 | 111 ± 20 | 0.076 |
Salb (gl/l) | 19.6 ± 3.9 | 20.7 ± 3.5 | 19.7 ± 3.7 | 20.7 ± 3.9 | 0.239 |
Upro (g/24 h) | 7.3 ± 4.0 | 6.7 ± 3.3 | 6.4 ± 2.8 | 6.9 ± 3.6 | 0.722 |
Anti-PLA2R positive,n(%) | 49 (94.2) | 70 (97.2) | 30 (96.8) | 41 (100) | 0.457 |
AKI stage, n (%) | |||||
1 stage | 37 (71.2) | 63 (87.5) | 22 (71.0) | 39 (95.1) | 0.005c |
2 stage | 13 (25.0) | 8 (11.1) | 8 (25.8) | 1 (2.4) | 0.006d |
3 stage | 2 (3.8) | 1 (1.4) | 1 (3.2) | 1 (2.4) | 0.849 |
GBM stage, n (%) | |||||
I stage | 40 (76.9) | 50 (69.4) | 22 (71.0) | 30 (73.2) | 0.827 |
II stage | 12 (23.1) | 22 (30.6) | 9 (29.0) | 11 (26.8) | 0.827 |
Infection, n (%) | 4 (7.7) | 5 (6.9) | 3 (9.7) | 2 (4.9) | 0.886 |
Thrombosis, n (%) | 0 (0) | 1 (1.4) | 0 (0) | 1 (2.4) | 0.622 |
Hypertensive nephropathy, n(%) | 41 (78.8) | 59 (81.9) | 24 (77.4) | 33 (80.1) | 0.951 |
Diabetes, n (%) | 12 (23.1) | 16 (22.2) | 7 (29.3) | 12 (24.0) | 0.848 |
MPCTX, n (%) | 23 (44.2) | 44 (61.1) | 9 (29.0) | 25 (61.0) | 0.009e |
FK506, n (%) | 17 (32.7) | 23 (31.9) | 10 (32.3) | 13 (31.7) | 1.000 |
CSA, n (%) | 7 (13.5) | 13 (18.1) | 4 (12.9) | 3 (7.3) | 0.462 |
RSAI, n (%) | 48 (92.3) | 64 (88.9) | 30 (96.8) | 37 (90.2) | 0.609 |
Diuretics, n (%) | 35 (67.3) | 5 (6.9) | 20 (64.5) | 3 (7.3) | < 0.001f |